Name: Yingjie Xu
Title： Principal investigator
Email: [email protected]
Tel: 17317361101
Research Interests
Yingjie Xu graduated from Shanghai Jiaotong University School of Medicine, department of clinical medicine, and obtained her doctoral degree from McGill University, Division of Experimental Medicine. Yingjie Xu has extensive experience in in vitro synthesis and delivery of chemically modified mRNA. During her postdoctoral period at Boston Children’s Hospital, she carried out pioneering work on the treatment of metastatic prostate cancer with PTEN deficiency by nanoparticle delivery of the tumor suppressor PTEN mRNA. Dr. Xu’s research group focuses on optimization of mRNA synthesis, and the development of mRNA-based therapeutics, including mRNA vaccine for infectious disease, cancer mRNA vaccines, mRNA-based cancer immune therapy as well as mRNA for protein replacement therapy.
Ten Selected Papers
*co-corresponding authors; #co-first authors
(1) Xia J, Zhang J, Wang L, Liu H, Wang J, Liu J, Liu Z, Zhu Y, Xu Y*, Yang W*, Yu Y*. Non-apoptotic function of caspase-8 confers prostate cancer enzalutamide resistance via NF-κB activation. 2021 Sep 4;12(9):833. doi: 10.1038/s41419-021-04126-4. (*Co-corresponding author)
(2) ·Zhang J, Yin Y, Wang J, Zhang J, Liu H, Feng W, Yang W, Zetter B, Xu Y*. Prohibitin regulates mTOR pathway via the interaction with FKBP8. Frontiers of Medicine. 2020, Dec 1
(3) ·Lu J, Lu G, Tan S, Xia J, Xiong H, Yu X, Qi Q, Yu X, Li L, Yu H, Xia N, Zhang T, Xu Y*, Lin J. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Research. 2020, 30（936-939）. (*Co-corresponding author)
(4) ·Saw PE, Zhang A, Nie Y, Zhang L, Xu Y*, Xu X. Tumor-associated fibronectin targeted liposomal nanoplatform for cyclophilin A siRNA delivery and targeted malignant glioblastoma therapy. Frontier in Pharmacology. 2018 (*Co-corresponding author)
(5) ·Islam MA, Xu Y#, Tao,W, Ubellacker JM, Lim M, Aum D, Lee GY, Zhou K, Zope HR,Yu M, Cao W, Oswald JT, Dinavand M, Mahmoudi M, Langer R, Kantoff PK, Farokhzad OC, Zetter BR, Shi J. Restoration of tumor suppression in vivo by systemic delivery of chemically modified PTEN mRNA nanoparticles. Nat. Biomed. Eng.2018 Sep 18 online. (*Co-first author)
(6) ·Xu Y, Yang W, Shi J, Zetter BR. Prohibitin 1 regulates tumor cell apoptosis via interaction with X-linked Inhibitor of Apoptosis Protein. J Mol Cell Biol. 2016 Jun; 8(3):282-5. doi: 10.1093/jmcb/mjw018.
(7) ·Zhu X, Xu Y #, Solis LM, Tao W, Wang L, Behrens C, Xu X, Zhao L, Liu D, Wu J, Zhang N, Wistuba II, Farokhzad OC, Zetter BR, Shi J. Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):7779-84. (*Co-first author)
(8) ·Shi J, Xu Y #, Xu X, Zhu X, Pridgen E, Wu J, Alexander V, Zetter BR, Farokhzad O. Hybrid Lipid-Polymer Nanoparticles for Sustained siRNA Delivery and Gene Silencing. Nanomedicine. 2014 Mar 17. pii: S1549-9634(14)00124-5. doi: 10.1016/j.nano.2014.03.006. (*Co-first author)
(9) ·Xu Y, Bismar TA, Su J, Xu B, Kristiansen G, Varga Z, Teng L, Ingber DE, Mammoto A, Kumar R, Alaoui-Jamali MA. Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J Exp Med. 2010 Oct 25;207(11):2421-37. Epub 2010 Oct 11.
(10) ·Xu Y, Benlimame N, Su J, He Q, Alaoui-Jamali MA. Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells. Br J Cancer. 2009 Feb 24;100(4):633-43. Epub 2009 Feb 3.
Collaborative Investigators
